The DOI matches its Crossref record.
Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring
Abstract
Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor markers play a critical role in the monitoring of patients. The patient’s clinical status and response to treatment can be evaluated rapidly using the tumor marker half-life (t1/2) and the tumor marker doubling time (DT). This report reviews the interest of determining these kinetic parameters for prostate-specific antigen, human chorionic gonadotropin, α-fetoprotein, carcinoembryonic antigen, cancer antigen (CA) 125, and CA 15-3. A rise in tumor markers (DT) is a yardstick with which benign diseases can be distinguished from metastatic disease, and the DT can be used to assess the efficacy of treatments. A decline in the tumor marker concentration (t1/2) is a predictor of possible residual disease if the timing of blood sampling is soon after therapy. The discrepancies in results obtained by different groups may be attributable to the multiplicity of immunoassays, the intrinsic characteristics of each marker (e.g., antigen specificity, molecular heterogeneity, and associated forms), individual factors (e.g., nonspecific increases and renal and hepatic diseases) and methods used to calculate kinetics (e.g., exponential models and timing of blood sampling). This kinetic approach could be of interest to optimize patient management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Differential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Lesko, L., & Atkinson, A. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.347 · Cited by 465
Barbet, J., Campion, L., Kraeber-Bodéré, F., & Chatal, J.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0044 · Cited by 407
Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
Gupta, D., & Lis, C. G. (2009) · Journal of Ovarian Research · doi:10.1186/1757-2215-2-13 · Cited by 208
Metadata
- Authors
- Bidart, J.-M., Thuillier, F., Augereau, C., Chalas, J., Daver, A., Jacob, N., Labrousse, F., & Voitot, H.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-10-01
- Volume
- 45
- Issue
- 10
- Pages
- 1695-1707
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2168001271
- Cited by
- 159
- References
- 0
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring. https://app.cochat.ai/papers/10.1093/clinchem/45.10.1695
- The paper
- Bidart, J.-M., Thuillier, F., Augereau, C., Chalas, J., Daver, A., Jacob, N., Labrousse, F., & Voitot, H. (1999). Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring. Clinical Chemistry. https://doi.org/10.1093/clinchem/45.10.1695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.